Solid state forms of fused heteroaromatic pyrrolidinones
Disclosed are chemical entities which are inhibitors of spleen tyrosine kinase (SYK), namely, chemical entities comprising 6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridine-3(2H)-one and certain solid state forms thereof. Also disclosed are methods of using the chemical entities to treat disorders such as a cancer.
1. A crystal form of 6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridine-3(2H)-one citrate, which is in substantially crystalline form, and is characterized by an X-ray powder diffraction (XRPD) pattern using Cu Kα radiation comprising peaks at 2θ angles of 9.4, 16.6, 17.4, 18.9, 19.2, and 20.7°±0.2 degrees.
2. The crystal form of claim 1 , characterized by an XRPD pattern using Cu Kα radiation comprising peaks at 2θ angles of 4.7, 9.4, 16.6, 17.4, 18.9, 19.2, 20.7, and 23.0°±0.2 degrees.
3. The crystal form of claim 1 , characterized by an XRPD pattern using Cu Kα radiation comprising peaks at 2θ angles of 4.7, 9.4, 13.0, 13.8, 14.1, 16.6, 17.4, 18.4, 18.9, 19.2, 20.7, 23.0, 23.3, 23.6, and 25.0°±0.2 degrees.
4. The crystal form of claim 1 , wherein the crystal form is not hygroscopic.
5. A pharmaceutical composition comprising the crystal form of claim 1 and one or more pharmaceutically acceptable carriers.
6. The pharmaceutical composition of claim 5 , which is suitable for oral administration.
7. The pharmaceutical composition of claim 6 , which is a dosage form selected from a capsule and a tablet.
8. The pharmaceutical composition of claim 7 , wherein the dosage form is a tablet.